Kv7 K+ Channels in Airway Smooth Muscle Cells as Target for Asthma Therapy by Kakad, Priyanka Prakash









A THESIS SUBMITTED TO  
THE FACULTY OF THE GRADUATE SCHOOL  
IN CANDIDACY FOR THE DEGREE OF  
MASTER OF SCIENCE  
IN 




PRIYANKA PRAKASH KAKAD 
CHICAGO, ILLINOIS 
AUGUST 2012 
Copyright by Priyanka P. Kakad, 2012 
All rights reserved. 
 iii 
ACKNOWLEDGEMENTS 
I would like to thank my advisor Dr. Kenneth L. Byron for all the advice, 
knowledge, support and encouragement he has given to me during the entire course 
of my study at Loyola. I am thankful to Dr. Byron for providing excellent training, 
always encouraging independent thinking and initiating thoughtful scientific 
discussions. His ways of conducting research have left a lasting impression on me. 
I am highly grateful toward Dr. Leanne Cribbs for serving as a mentor and 
providing excellent training to me in the qRT-PCR expression studies that make a 
significant part of this thesis. I would like to acknowledge the members of my thesis 
committee, Dr. Lee Cera and Dr. Leanne Cribbs for all the insightful discussions, 
helpful critique, and worthy suggestions on my research. They have imbibed in me a 
unique quality of viewing my own research in the perspective of a third person.  
I would also like to thank the fellow members of Byron laboratory for 
providing extremely friendly and learning atmosphere in the laboratory. Especially, 
I would like to thank Dr. Lioubov Brueggemann for training me in precision cut-lung 
slices studies, electrophysiological studies and other important techniques during 
my stay in the laboratory. I would also like to thank Dr. Bharath Mani and Valerie 
Hummert for their friendship, help and support. They were part of many 
discussions, scientific and otherwise.  
 iv 
Importantly, I would like to thank my family and friends back in India for 
their love and support throughout my life. I thank my parents for their constant 
encouragement and motivation all the times. I am thankful to my brother, sisters 
and my in-laws for all their efforts in shaping up my career. I owe my deepest 
gratitude to my husband Dr. Prakash Palde, who always supported and believed in 
my strength during the toughest times of my life. He has always inspired me to be 
motivated. Last but not the least; I am thankful to my very lovely daughter Siya for 
being the nicest baby on the earth and allowing me to focus on my research. She was 
born mid-way during the course of my study and since then has been the biggest joy 
and love in our lives.  
 
Priyanka 
To my wonderful family for 
all their love, care and support 
 vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES vii 
LIST OF FIGURES viii 
LIST OF ABBREVIATIONS x 
ABSTRACT xiii 
CHAPTER 1: PATHOPHYSIOLOGY OF ASTHMA 1 
 Regulation of calcium signaling in ASMCs 2 
 Ca2+ influx via VSCC in ASMCs 5 
 K+ channels and their role in maintaining Em on ASMCs 6 
 Structure, assembly and function of Kv7 K+ channels 10 
 Biophysical characterization of K+ currents in ASMCs 13 
 Summary 18 
 
CHAPTER 2: PROJECT OVERVIEW 20 
 Objective 20 
 Rationale 20 
 Hypothesis 21 
 Specific Aim 1 22 
 Specific Aim 2 22 
 Significance 22 
 
CHAPTER 3: GUINEA PIG MODEL OF AIRWAY HYPERRESPONSIVENESS 23 
 Animal welfare and housing 25 
 Induction of AHR in guinea pigs 25 
 Troubleshooting 28 
 Summary  28 
 
CHAPTER 4: EXPRESSION OF Kv7 CHANNELS IN NORMAL AND  
 ASTHAMATIC AIRWAYS 29 
 Isolation of Airway Smooth Muscle Cells (ASMCs) 30 
 qRT-PCR studies in guinea pig and human ASMCs 32 
 Results  35 
 
CHAPTER 5: FUNCTIONAL ROLE OF Kv7 CHANNELS IN AIRWAYS 39 
 Preparation of Precision-Cut Lung Slices (PCLS) 40 












LIST OF TABLES 
Table   Page 
 1. Guinea pig primers 34 
 2. Human primers 34 
 ix 
LIST OF FIGURES 
Figure  Page 
 1.  Regulation of calcium signaling in ASMCs 4 
 2.  Resting membrane potential on ASMCs and threshold for activation  
     of VSCC 6 
 
 3.  Two concentration-dependent signaling pathways of [Arg8]  
     vasopressin (AVP) in VSMCs 8 
 
 4.  K+ channels and their role in controlling Em on ASMCs 9 
 
 5.   Structural aspects of Kv7 K+ channels 11 
 
 6.  Biophysical characterization of K+ currents in guinea pig ASMCs 15 
 
 7.  Pharmacology of Kv7 currents in guinea pig ASMCs 16 
 
 8.  Suppression of Kv7 currents by bronchoconstrictor agonists in  
    guinea pig ASMCs and their restoration by the Kv7 channel  
    activator flupirtine 17 
 
 9.  Hypothesis for the research presented in this thesis 21 
 
10.  Flow chart depicting various treatment stages in the development  
     of guinea pig model of airway disease 26  
 
11.  Stepwise procedure for isolation of guinea pig ASMCs 31  
 
12.  Multiple KCNQ subtypes are expressed in guinea pig and human 
     airway smooth muscle cells (ASMCs) 35  
 
13.  Immunohistochemistry studies supporting expression of Kv7 
     channels in airways 36 
  
14.   Comparing expression pattern of different Kv7 channel subtypes  
   in saline-control and allergen-sensitized guinea pig ASMCs 37 
 x 
15.  Image demonstrating luminal area measurement of PCLS 
    Preparation 43 
  
16.  Passive sensitization of airway from guinea pig model of AHR  
   using ovalbumin (OVA) 45  
 
17.   Dose-response curves for histamine in PCLS preparations from  
  saline-control and allergen-sensitized guinea pig airways 47  
 
18.   Dose-response curves for methacholine (MC) in PCLS preparations  
   from saline-control and allergen-sensitized guinea pig airways 48 
 
19.  Kv7 Channel activator retigabine attenuated histamine induced 
constriction of saline-control andallergen-sensitizedairways 49  
 
20.   Functional Kv7 channels are required for maintaining resting  
   diameter of small airways in human lung slices 50  
xi 
LIST OF ABBREVIATIONS 
Ach: Acetycholine 
AHR:     Airway Hyperresponsiveness 
AKAP: A-Kinase Anchoring Protein 
ASMCs: Airway Smooth Muscle Cells 
AVP: Arginine-(8)-Vasopressin 
Ca+2: Calcium ion 
[Ca+2]cyt:  Cytosolic calcium concentration 
CaM Calmodulin 
COX-2:     Cyclooxygenase-2 
DAG: Diacylglycerol 
DMEM:  Dulbecco's Modified Eagle Medium 
EC50: Half-Maximal Effective Concentration 
Emax: Maximal Effect in dose-response curve 
Gd3+: Gadolinium 
Gq:    Class of guanine-nucleotide binding protein that activates 
phospholipase C 
GPCR: G Protein Coupled Receptor 
HBSS: Hank’s Balanced Salt Solution 




K+:     Potassium ions 
KATP: ATP sensitive potassium channels 
KCNQ:     Gene that encodes Kv7 channel proteins 
Kv: Voltage sensitive potassium channels 
Kv7:    Class of voltage-gated potassium channels  
LTD4:     Leukotriene D4 
L-type VSCC: Long-Lasting Voltage-Sensitive Calcium Channels 
MLCK: Myosin Light Chain Kinase 
mRNA: Messenger RNA 
Na+: Sodium ions 
NSAID: Non-Steroidal Anti-Inflammatory Drugs 
OVA: Ovalbumin 
PCLS:     Precision Cut Lung Slices 
PIP2: Phosphatidylinositol-4,5-Bisphosphate 
PKC:     Protein Kinase C 
PLC:     Phospholipase C 
PSS: Physiological Saline Solution 
ROCC:  Receptor Operated Calcium Channels 
qRT-PCR:    Quantitative Real Time Polymerase Chain Reaction 
SOCC: Store Operated Calcium Channels 
SR:  Sarcoplasmic Reticulum 
xiii 
TRP: Transient Receptor Potential Channel Family 
Em: Membrane voltage or membrane potential 
VSCC:     Voltage-Sensitive Calcium Channels 
VSMCs:     Vascular Smooth Muscle Cells 




Asthma continues to be one of the major global health problems with the 
current therapies being effective yet inadequate in controlling the disease.  Asthma 
is commonly associated with airway hyperresponsiveness (AHR) involving 
hypercontraction of airway smooth muscle cells (ASMCs).  Despite extensive 
research, the molecular mechanisms of AHR are poorly understood, thus preventing 
development of specific and effective therapies in the treatment of asthma.  The 
overarching goal of the research presented in this thesis is to elucidate the 
mechanisms underlying AHR in asthma.  This will not only help us gain a better 
insight into the pathophysiology of asthma, but may further lead to the discovery of 
novel and improved therapeutic agents.  Our research specifically focuses on 
investigating the role played by Kv7 voltage-activated potassium channels in the 
pathophysiology of AHR, and evaluating the significance of Kv7 channel regulation 
in the treatment of asthma. 
Kv7 channel expression in various excitable cells and their functional role in 
maintaining the cell membrane in a hyperpolarized state have been studied in great 
detail.  However, their expression and function in ASMCs was largely unknown.  
Through the research presented in this thesis, we provide the first evidence for the 
expression of multiple Kv7 channel subtypes in guinea pig and human ASMCs using 
qRT-PCR studies. Our further investigation of expression of Kv7 channels in 
xv 
allergen-sensitized guinea pig ASMCs reveal a trend indicating a decrease in the 
expression of all KCNQ (genes encoding Kv7 channels) isoforms in allergen-
sensitized guinea pig airways compared to the saline-treated control animals.  This 
decreased Kv7 channel expression would be expected to cause greater membrane 
depolarization and increased contractility of airways to various stimuli, common 
feature of AHR.  To investigate the function of Kv7 channels in ASMCs we further 
conducted ex vivo studies using precision-cut lung slices (PCLS).  Consistent with the 
existing scientific literature, our PCLS demonstrate that the guinea pig airways 
become hypersensitive to bronchoconstrictor agonists post-bronchial provocation, 
with an increase in potency and magnitude of constriction in response to 
bronchoconstrictor agonist treatment. Importantly, our studies also reveal that this 
increased, hypersensitive response of allergen-sensitized airways to 
bronchoconstrictor agonists can be attenuated by treatment with the clinically used 
Kv7 channel activator, retigabine.  This protective effect of a Kv7 channel activator is 
likely due to an increase in activity of remaining Kv7 channels in allergen-sensitized 
airways, thereby improving control on membrane polarization. 
In summary, our observations reported in this thesis provide new insights 
into how Kv7 channel expression and function in airways play a vital role in 
regulating airway diameter. Importantly, the attenuation of bronchoconstrictor 
agoinst-mediated airway constriction by a clinically used Kv7 channel activator in 
allergen-sensitized airways as observed in our studies provides a promising new 





PATHOPHYSIOLOGY OF ASTHMA 
Asthma continues to be one of the major global health problems. According 
to a recent update from the World Health Organization (WHO), approximately 235 
million people in the world currently suffer from asthma (WHO fact sheet, 2011). A 
recent national health statistics report indicates that the prevalence of asthma is on 
the rise in the United States with 24.6 million people (8.2% of American population) 
currently diagnosed with this disease (Akinbami et al. 2011). Asthma is also the 
most common chronic disease afflicting children with its prevalence in children 
being higher than that in adults. 
The current therapy for asthma, constituting mainly the inhaled 
corticosteroids and the long-acting inhaled β2-agonists, is effective and relatively 
inexpensive, but also has a number of limitations. Primarily, it is a general strategy 
targeted toward controlling and containing asthma by suppressing its symptoms. A 
significant variability in patients’ responses to the current therapies has been 
reported, especially in the case of inhaled corticosteroids (Szefler et al. 2010). 
Severe cases of asthma accounting for approximately 10 % of the patient population 
are mostly untreatable with the current lines of treatment. Hence the quest for 
newer, more specific and curative therapies for asthma still continues. These 
therapies are likely to emerge from novel drug classes that act on biological targets 
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specific to asthma. Such specific and druggable asthma targets can only be identified 
via in-depth understanding of the pathophysiology of this heterogeneous and 
complex disease. Tremendous efforts are currently underway to discover complex 
molecular pathways that underlie asthma symptoms (Holgate et al. 2011), however, 
the pathophysiology of asthma still remains poorly understood.  
According to current understanding, the three fundamental components in 
pathogenesis of asthma are airway inflammation, airway remodeling and airway 
hyperresponsiveness (AHR), which together lead to a progressive decline of normal 
lung function (Bousquet J et al. 2000).  AHR is defined as excessive contraction of 
airway smooth muscle cells (ASMCs) in response to a variety of stimuli. A number of 
different pharmacological, chemical and physical stimuli lead to such an 
exaggerated response. However, the molecular mechanisms underlying AHR remain 
unclear.  Elucidating the molecular mechanisms of AHR will undoubtedly provide 
better insight into this intricate process while simultaneously uncovering novel 
therapeutic targets for improved treatments in asthma.  
Regulation of calcium signaling in ASMCs 
It is well known that intracellular calcium regulation plays a central role in 
ASMCs contraction (Armani Y et al. 2002). An increase in the cytosolic calcium 
concentration ([Ca2+]cyt) triggers bronchoconstriction. Various bronchoconstrictor 
agonists like acetylcholine (ACh), leukotriene D4 (LTD4), endothelin and histamine 
activate the Gq/11-coupled receptors on ASMCs leading to an increase in [Ca2+]cyt 
(Penn et al. 2008). The local concentrations of these bronchoconstrictor agonists 
have been found to elevate during ASMC hypercontraction (Belmonte 2005; Smith 
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et al. 2005; Hamid Q et al. 2009). Studies have shown that the exposure of ASMCs to 
these bronchoconstrictor agonists results in a biphasic elevation of [Ca2+]cyt (Hirota 
et al. 2007; Jude et al. 2008) (Figure 1). The initial rapid or transient phase of 
[Ca2+]cyt elevation is mediated by release of calcium from inositol-1,4,5-triphosphate 
(IP3)-sensitive intracellular calcium stores also called sarcoplasmic reticulum (SR). 
This transient increase in [Ca2+]cyt is usually followed by a sustained elevation of 
[Ca2+]cyt that is maintained by influx of Ca2+ across the plasma membrane from the 
extracellular space. This sustained elevation of Ca2+ plays an important role in 
prolonging ASMC contraction.  Influx of Ca2+ is believed to occur via several ion 
channels on the surface of ASMCs. There are differences in opinion about the 
contribution of various Ca2+ ion channels on ASMCs in agonist-mediated Ca2+ influx 
(Janssen et al. 2002). In general, two mechanisms being debated are the voltage-
independent calcium influx and voltage-dependent Ca2+ influx (Hirota et al. 2007). 
The voltage-independent calcium influx is proposed to happen via store-operated 
calcium channels (SOCC), receptor-operated calcium channels (ROCC) and/or non-
selective cation channels belonging to the Transient Receptor Potential (TRP) 
channel family. The influx of Ca2+ through SOCC can be triggered by the emptying of 
internal Ca2+ stores (SR) (Ay et al. 2004), while the ROCC can be directly activated 
by the diacylglycerol (DAG) produced as a result of agonist-mediated activation of 
membrane receptors (Murray et al.  1993). The TRP family of channels have been 
shown to be involved in Ca2+ influx in other types of smooth muscle cells. A similar 
role was proposed for them in ASMCs after they were found to be expressed in 
human ASMCs (Ong et al. 2004; Gosling et al. 2005; Perez-Zoghbi et al. 2009). 
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Voltage-dependent calcium influx in ASMCs is proposed to proceed via voltage 
sensitive calcium channels (VSCC), similar to the process in other smooth muscle 
cells (Perez-Zoghbi et al. 2009). There is evidence, both in support and against 
significant contributions of these different channel subtypes to the sustained phase 
elevation of Ca2+.  
 
Figure 1: Regulation of calcium signaling in Airway Smooth Muscle Cells (ASMCs). 
Bronchoconstrictor agonists bind to their receptors on ASMCs leading to activation of phospholipase 
C (PLC) followed by synthesis of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from 
membrane lipids. IP3 in turn stimulates the release of Ca2+ from the sarcoplasmic reticulum (SR) 
followed by repetitive release and uptake of Ca2+ resulting in Ca2+ oscillations. Calcium influx  across 
the plasma membrane (sustained phase) may then occur via a number of Ca2+ channels like Store 
Operated Calcium Channels (SOCC), Receptor-operated calcium channels (ROCC), Transient Receptor 
Potential (TRP) family of channels and voltage sensitive calcium channels (VSCC). Elevated ca2+ by 
these two mechanisms binds to calmodulin (CaM), thereby activating myosin light chain kinase 
(MLCK), which phosphorylates MLC and initiates actomyosin cross-bridge cycling thus leading to 
bronchoconstriction. The individual contribution of these channels in Ca2+ influx during the sustained 























Ca2+ influx via VSCC on ASMCs 
VSCCs open (activate) in response to membrane depolarization. VSCCs on 
ASMCs have threshold for steep voltage-dependent activation ranging from -45 to -
25 mV, with maximal activation at 0 to +20 mV (Figure 2). They are known to be 
blocked by dihydropyridine based compounds (Hirota et al. 2007). All these 
properties resemble the characteristic properties of “L-type” or long-lasting voltage-
sensitive calcium channels. The resting membrane potential (Em) of ASMCs ranges 
from -60 to -45 mV (Liu et al. 2005), so it is unlikely for L-type VSCC to be 
appreciably active at the resting state of the ASMC membrane. However, membrane 
depolarization is likely to result in activation of L-type VSCC and influx of Ca2+. In 
fact, many bronchoconstrictor agonists depolarize the ASMC membrane to 
potentials positive to the L-type VSCC activation threshold (Hirota et al. 2007). 
Therefore, L-type VSCC are likely to be the key contributors toward the influx of Ca2+ 
from the extracellular space into the cytoplasm, eventually leading to 
bronchoconstriction. There is ample evidence in the literature supporting 
involvement of L-type VSCC in elevating [Ca2+]cyt (Jude et al. 2008; Perez-Zoghbi et 
al. 2009), particularly at low agonist concentrations (Barnes et al. 1985).  A number 
of studies have also shown that agonist-induced Ca2+ signaling in ASMCs is 
attenuated by L-type Ca2+ channel blockers (Solway et al. 1985; Thirstrup et al. 
1997; Hirota et al. 2003) emphasizing the role played by L-type VSCC in the calcium 
influx during the sustained phase of agonist induced airway constriction.  
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Figure 2: Resting membrane potential on ASMCs and threshold for activation of L-type VSCC 
depicting their role in mediating influx of Ca+2 from extracellular space upon membrane 
depolarization by bronchoconstrictor agonists. The width of the cone reflects fractional magnitude of 
Ca+2 current at a value of membrane potential (Em).   
Therapeutic potential of calcium channel blockers has been evaluated 
previously in a number of clinical trials (Fish et al. 1984). Results from these clinical 
trials suggested that calcium channel blockers like verapamil and nifedipine were 
effective in dilating airways, but only in a subset of patients. Administration of these 
calcium channel blockers showed significant protection against bronchoconstriction 
induced by exercise, hyperventilation, histamine and methacholine (Barnes et al. 
1983). Their therapeutic potential, however, was not fully explored mainly due to 
their limited potency and systemic adverse effects.  
K+ channels and their role in maintaining the Em on ASMCs 
 K+ channels play an important role in Ca2+ signaling through their ability to 
maintain a negative membrane potential. As indicated before and depicted in figure 
2, ASMCs have a resting membrane potential of -60 to -45 mV (Liu et al. 2005). In 
human and guinea pig ASMCs the membrane potential is reported to oscillate in a 









membrane depolarization by 
bronchoconstrictor agonists
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However, these waves are rarely converted in to spiking action potentials as ASMC 
membrane displays strong outward rectification under resting conditions. This 
outward rectification is mainly in the form of K+ efflux via K+ channels on ASMC 
membrane, thus maintaining a hyperpolarized state of the membrane (Thirstrup et 
al. 2000). It therefore stands to reason that inhibition of K+ channels would result in 
membrane depolarization and consequent activation of other voltage-dependent 
channels on the ASMC membrane, including VSCC, which would promote Ca2+ influx 
and ASMC contraction.  
Based on this principle, our laboratory has previously reported such 
mechanism for the Gq/11-coupled receptor pituitary hormone [Arg8]vasopressin 
(AVP) in its vasoconstrictor actions on vascular smooth muscle cells (VSMCs). It is 
generally accepted that AVP leads to vasoconstriction by the activation of PLC and 
consequently the release of Ca+2 from SR. The half-maximal activation of PLC 
requires nano-molar concentrations of AVP, however, the circulating AVP 
concentrations are usually in the pico-molar range (Doyle et al. 1985). Our 
laboratory observed that at physiologically relevant (low) concentrations, AVP acts 
exclusively by activating the L-type VSCC in VSMCs (Henderson et al. 2007).  It does 
so by suppressing the activity of Kv7 channels via a protein kinase C (PKC) -
dependent pathway (Figure 3) (Brueggemann et al. 2007; Mackie et al. 2008a). 
These results provide strong evidence for Kv7 channels playing a pivotal role in 
maintaining a negative resting potential in the vascular myocytes and opposing the 
opening of VSCC. Suppression of Kv7 channel activity by physiologically relevant 
concentrations of AVP results in membrane depolarization and activation of VSCC. 
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Through the research presented in this thesis, we propose a similar mechanism for 
bronchoconstrictor agonist-mediated ASMC contraction (please refer to chapter 2 
for further discussion).  
 
Figure 3: Two concentration-dependent signaling pathways of [Arg8] vasopressin (AVP) in 
VSMCs.  Nanomolar (nM) concentrations of AVP acutely activate the well-accepted AVP signaling 
pathway that involves activation of phospholipase C (PLC) and inositol 1,4,5-trisphosphate (IP3)-
mediated calcium (Ca2+) release. On the other hand, picomolar (pM) concentrations of AVP induce 
voltage-sensitive Ca2+ entry via protein kinase C (PKC) activation and inhibition of voltage-activated 
K+ channels (Kv7). 
Three different types of K+ channels are known to be expressed in ASMCs, 
Ca+2-activated potassium channels (KCa+2), ATP-sensitive potassium channels (KATP) 
and voltage-gated potassium channels (Kv) (Figure 4). Previous studies have shown 
that KCa+2 channels do not contribute significantly toward controlling the Em on 
ASMCs (Liu et al. 2003a). KCa+2 channel blocker used in the study had no effect on 
resting membrane potential in rat ASMCs. Similarly, KATP channel inhibitor 


















ASMCs, indicating that KATP do not control the Em in ASMCs (Liu et al. 2003b; Zhao et 
al. 2005).  
 
Figure 4: K+ channels and their role in controlling Em on ASMCs. Three different types of K+ 
channels are known to be expressed in ASMCs: KCa, KATP and Kv. Blocking the activity of KCa and 
KATP channels has been shown to have no effect on the Em indicating that they do not govern the Em 
on ASMCs. Evidences suggest that Kv channels are important determinants of Em, however, the Kv1 
channels that were found to be expressed in ASMCs are not likely to contribute significantly to the 
resting Em due to their relatively positive threshold of activation (-40 mV). Kv7 channel, on the other 
hand, have threshold of activation that lies in the range of the resting Em on ASMCs making them 
likely candidates governing the Em on ASMCs. 
Kv channels are voltage-sensitive, Ca+2-independent K+ channels that are 
considered the most important class of K+ channels in determining Em on ASMCs 
(Hall et al. 2000). A few subtypes of Kv channels (Kv1.1, Kv1.2 and Kv1.5) have been 
found to be expressed in human ASMCs (Adda et al. 1996). The threshold for 
voltage-dependent activation of Kv1 channels lies positive to -40 mV. Contradictory 
to literature reports, it seems unlikely for Kv1 channels with a relatively positive 
threshold of activation to contribute to the resting membrane potential (-45 to -60 
mV) on ASMCs. Kv7 channels, another type of voltage-activated potassium channels, 
have a threshold for activation at ~ -60 mV. Hence, they seem more likely 
candidates governing resting membrane potential on ASMCs compared to Kv1 
Em = -45 to -60 mV
ASMC
(No effect on Em)
~ -40 mV
Kv7





(No effect on Em)
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subtypes. However, their expression and function in ASMCs was largely unknown 
before the start of the investigation presented in this thesis.  
Structure, assembly and function of Kv7 channels 
The Kv7 family of voltage-gated K+ channels is encoded by KCNQ genes. Five 
subtypes have been identified so far: Kv7.1 – Kv7.5 (KCNQ1-5 as an alternative 
terminology) (Gutman et al. 2003). Kv7 channels are composed of four subunits, 
each consisting of six α-helical transmembrane domains (S1-S6) and a single P-loop 
region (Figure 5). Of particular importance is the fourth transmembrane domain 
(S4) that consists of regularly-spaced, positively-charged amino acids (arginine) 
(Schroeder et al. 2000a), which plays an essential role in sensing membrane 
potential and triggering conformational changes. The P-loop consists of potassium 
signature sequence (TXXTXGYG) that serves as a characteristic feature of voltage-
gated K+ channels (Heginbotham et al. 1992).  
Functional Kv7 channels require homomeric or heteromeric assemblies of 
four subunits (tetramers). While the Kv7.1 (or KvLQT1) subtype has not been found 
to co-assemble with other Kv7 subunits (Schwake et al. 2003), the Kv7.3 subunit has 
shown the capability to form hetero-tetramers with all other subunits except for 
Kv7.1 (Jentsch, 2000). Unlike other Kv channels, the tetramerization domain in Kv7 
channels lies in the cytosolic C-terminus rather than the transmembrane domain 1 
(Wehling et al. 2007). Besides this, the C-terminus also carries binding sites for 
various regulatory elements such as phosphatidylinositol-4,5-bisphosphate (PIP2) 
(Zang et al. 2003), calmodulin (CaM) (Yus-Najera et al. 2002), A-kinase anchoring 
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protein (AKAP) (Hoshi et al. 2003), and phosphorylation sites for protein kinase C 
(PKC) (Hoshi et al. 2003). 
 
Figure 5: Structural aspects of Kv7 K+ channels. (+) indicates the positively charged amino acid 
arginine in transmembrane domain 4 (S4). TXXTXGYG is the potassium signature sequence in the P-
loop region. The picture on the right shows assembly of Kv7.2-Kv7.3 hetero-tetrameric channel. 
 
A particular distribution pattern has been observed for different subtypes of 
Kv7 channels. Kv7.1 subtype has been found to be expressed predominantly by 
cardiac myocytes, whereas Kv7.2–7.5 have been considered largely ‘neuronal' 
(Jentsch, 2000; Schroeder et al., 2000a). The Kv7.4 subtype has been found to have 
specialized cellular location in auditory neurons (Kharkovets et al., 2000). Adult rat 
aorta and rat mesentric artery has been found to express Kv7.1, Kv7.4 and Kv7.5, 
whereas only Kv7.5 was shown to be expressed in embroyonic rat aorta derieved 
(A7r5) smooth muscle cells (Brueggemann et al. 2007; Mackie et al. 2008a). More 
recently, Kv7.1 and Kv7.5 subtypes were also shown to be expressed in visceral and 
myometrial smooth muscle (Jepps et al 2009; McCallum et al. 2008).  Mutations in 
the KCNQ genes encoding different Kv7 channel subtypes are known to be the 
















underlying causes of various diseases. For example, mutations in Kv7.1 channels 
result in cardiac arrhythmias, mutations in Kv7.2 and Kv7.3 result in neuronal 
excitability (Jentsch, 2000), whereas mutations in Kv7.4 result in deafness (Robbins 
et al. 2001).  Therefore, different Kv7 channel subtypes have been found to be 
attractive molecular targets for novel anti-epileptic (Main et al. 2000), anti-migraine 
(Gribkoff 2003) and neuroprotective (Jensen 2002) agents.  
As far as pharmacological regulation of Kv7 channels with synthetic small 
molecules is concerned, a number of relatively selective Kv7 channel blockers and 
activators have been developed over the years (Xiong et al. 2008). Chromanol 293B 
is known as a selective Kv7.1 channel blocker (Busch et al. 1997; Schroeder et al. 
2000b), although it also partially inhibits Kv7.5 currents at concentrations higher 
than 100 µM (Lerche et al. 2000). Linopirdine (DuP 996, 1-phenyl-3,3-bis(pyridin-4-
ylmethyl)-1,3-dihydro-2H-indol-2-one) and its more potent analog XE991 (10,10-
bis(4-Pyridinylmethyl)-9(10H)-anthracenone) (Zaczek et al. 1998) are widely used, 
relatively selective blockers of all Kv7 channels at concentrations below 10 µM 
(Mackie et al. 2008b). At higher concentrations these compounds can potentially 
block other types of K+ channels (Schnee et al. 1998). Among the Kv7 channel 
activators, flupirtine (ethyl-N-[2-amino-6-(4-fluorophenylmethylamino)pyridin-3-
yl]carbamate) and retigabine (ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]-
phenyl]carbamate) have found wide usage. Flupirtine is used clinically as a non-
opioid analgesic with muscle relaxant properties (Devulder 2010), while retigabine 
is used as an anticonvulsant in the treatment of epilepsy (Harden 2012). Retigabine 
selectively activates Kv7.2–7.5 at concentrations up to 100 μM, beyond which it also 
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activates Kv7.1 channels (Tatulian et al. 2001; Schenzer et al. 2005; Wuttke et al. 
2005). Our laboratory has recently shown that the cyclooxygenase-2 (COX-2) 
enzyme inhibitor celecoxib (Celebrex®), and its COX-2 independent structural 
analog 2,5-dimethylcelecoxib (DMC) (Schönthal et al. 2008), dramatically enhanced 
Kv7 K+ currents and suppressed L-type VSCC channels in A7r5 rat aortic smooth 
muscle cells (Brueggemann et al. 2009). But another popular COX-2 inhibitor, 
rofecoxib (Vioxx®, withdrawn from the market), which is known to have adverse 
cardiovascular effects upon long-term treatment, did not show enhancement of Kv7 
K+ currents. These findings provides a likely mechanistic basis for differential 
cardiovascular risk profiles of COX-2 enzyme inhibitors used as non-steroidal anti-
inflammatory drugs (NSAID). 
Biophysical and pharmacological characterization of K+ currents in ASMCs 
In parallel to the investigation presented in this thesis on expression and 
function of Kv7 channels in ASMCs, our laboratory has carried out 
electrophysiological characterization of K+ currents in ASMCs with an objective to 
detect Kv7 currents in ASMCs, and determine their contribution to the total currents 
from all voltage-dependent potassium channels (Kvtotal) in ASMCs. Among the 
typical characteristic features that differentiate Kv7 currents from other Kv currents 
is that they display slow activation and deactivation kinetics, Kv7 channels typically 
display very little or no deactivation even during sustained depolarization, and 
some exibit a relatively negative threshold of activation (Jensen et al. 2007; Mackie 
et al. 2008b). The non-inactivating nature of Kv7 channels is considered 
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fundamental to their role in stabilizing the resting membrane potential in excitable 
cells like neuronal cells.  
In order to detect and measure the contribution of Kv7 currents in ASMCs, 
our laboratory recorded K+ currents in freshly dissociated guinea pig and human 
ASMCs. The whole cell perforated patch configuration was used to measure 
membrane currents under voltage-clamp conditions. Amphotericin B was added to 
the internal solution for membrane patch perforation. To isolate Kv7 currents, if 
present, 100 µM gadolinium(III) chloride (GdCl3) was added to external solutions 
based on the methods already developed in our laboratory (Brueggemann et al. 
2007; Mackie et al. 2008a). Use of 100 µM GdCl3 reversibly shifted the V0.5 activation 
of 4-aminopyridine sensitive Kv currents to more positive voltages, thus enabling 
measurements of purely Kv7 currents at voltages negative or equal to -20 mV. The 
currents recorded from guinea pig ASMCs (at voltages ≤ -20 mV) showed all the 
characteristic features of Kv7 currents: (i) slow kinetics of activation with no 
apparent inactivation during a 5s voltage step (Figure 6A); (ii) voltage-dependent 
activation with a very negative threshold (~ -60mV) and a half-maximal potential of 
activation (V0.5) of ~-31 mV (Figure 6B; Figure 7C & 7E); (iii) reversible 
enhancement by selective activators of Kv7.2-7.5 channels, flupirtine and retigabine, 
accompanied by a shift of the activation curve to more negative voltages (Figure 7); 
(iv) complete and irrever-sible suppression by the Kv7 channel blockers linopirdine 
(Figure 7B & 7D) and XE991 (Brueggemann et al. 2012). As discussed earlier, 
neuronal and vascular Kv7 channels are known to be inhibited upon activation of 
Gq/11-coupled receptors (Delmas et al. 2005; Mackie et al. 2008a). After biophysical 
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and pharmacological characterization 
of Kv7 currents in guinea pig ASMCs, our laboratory was interested in testing the 
ability of Gq/11-coupled bronchoconstrictor agonists (methacholine and histamine) 
to suppress the Kv7 currents in guinea pig ASMCs. A rapid and near complete 
inhibition of Kv7 currents was observed upon application of 100 nM methacholine. 
However, the currents were partially restored within 1-2 min to about 40% of the 
control levels while methacholine was still present (Figure 8A). Approximately 
60% reduction of Kv7 currents was observed at all voltages positive to -24mV as a 
sustained effect of methacholine in 100 nM concentration (Figure 8B & 8E). Most 
importantly, treatment with Kv7 channel activator flupirtine (10 µM) was found to 
restore the amplitude of Kv7 currents post-methacholine suppression to 64% of 
control (Figure 8B & E). Repeating these studies with histamine, another  
 
 
Figure 6: Biophysical characterization of K+ currents in guinea pig ASMCs. A. Representative 
traces of the current recorded using a 5s voltage step protocol depicted below (from -64 mV holding 
voltage, cell capacitance (C) = 15 pF). B. Averaged fractional conductance plots calculated from 
steady-state Kv7 currents fitted to a Boltzmann distribution (V0.5 = -31.0 ± 1.5 mV, n=13). (Adapted 



























Figure 7: Pharmacology of Kv7 currents in guinea pig ASMCs. A. Representative traces of Kv7 
currents recorded in control (i) and in the presence of 10 µM flupirtine (ii) with a voltage step 
protocol from -4 mV holding voltage. B. I-V relationships of Kv7 currents recorded in ASMCs before 
(control, filled circles, n=5), after 5 min treatment with 10 µM flupirtine (open circles, n=5) and after 
5 min treatment with linopirdine (10 µM, filled triangles, n=5). C. Averaged fractional conductance 
plots calculated from steady-state Kv7 currents measured in ASMCs in control (filled circles) and in 
the presence of 10 µM flupirtine (open circles) (n= 10) fitted to a Boltzmann distribution. D. I-V 
relationships of Kv7 currents normalized to control currents measured at +1 mV before (control, 
filled circles, n=4), after 5 min treatment with 1 µM retigabine (open circles, n=4) and after 5 min 
treatment with 10 µM linopirdine in the presence of 1 µM retigabine (filled triangles, n=5). E. 
Averaged fractional conductance plots calculated from steady-state Kv7 currents measured in ASMCs 
in control (filled circles,) and in the presence of 1 µM retigabine (open circles) fitted to a Boltzmann 




































































Figure 8: Suppression of Kv7 currents by bronchoconstrictor agonists in guinea pig ASMCs 
and their restoration by the Kv7 channel activator flupirtine (F). A. The time course of Kv7 current 
inhibition was recorded in ASMCs, at -20 mV holding voltage in control (2 min) following by methacholine 
application (100 nM for 3 min). After an additional 1 min recording flupirtine (10 µM) was applied in the 
presence of methacholine (C= 21 pF, representative of 4 similar experiments). B. Average I-V relationships of 
Kv7 currents recorded from -4 mV holding voltage in ASMCs before (control, filled circles, n=4), during 
treatment with 100 nM methacholine (open circles, n=4) and in the presence of XE991 (10 µM, filled triangles, 
n=3) applied in the end of each experiment. C. Dose-dependent suppression of Kv7 currents recorded at -20 mV 
holding voltage was observed upon application of histamine (3-30 µM, indicated by arrows).  D. Average I-V 
relationships of Kv7 currents recorded from -4 mV holding voltage and normalized to control currents recorded 
at +1mV in control (filled circles, n=4), in the presence of 30 µM histamine (open circles, n=4) and in the 
presence of XE991 (10 µM, filled triangles, n=4). E. Normalized currents recorded at -20mV in control (black 
bars), in the presence of agonists (open bars: His- 30 µM histamine, n=4; MC- 100nM methacholine, n=4); in the 
presence of agonists plus 10 µM flupirtine (striped bars: His+F - 10 µM flupirtine in the presence of 30 µM 
histamine, n=4; MC+F - 10 µM flupirtine in the presence of 100nM methacholine, n=4) and in the presence of 10 
µM XE991 (n=4). * significant difference from control (P< 0.05, one way ANOVA). # significant difference from 
all other treatment (P< 0.05, one way ANOVA). (Adapted from: Brueggemann LI, Kakad PP, et al. (2012) Am J 
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bronchoconstrictor agonist, showed suppression of Kv7 currents in airway 
myocytes in a dose-dependent manner (Figure 8C). Histamine-induced Kv7 current 
inhibition was transient at agonist concentrations from 1-10 µM, but application of 
30 µM histamine induced sustained current inhibition at all voltages positive to -29 
mV (Figure 8C-E). Subsequent addition of flupirtine (10 µM) in the continued 
presence of 30 µM histamine completely restored remaining Kv7 current amplitude 
to the values measured prior to histamine treatment (Figure 8E).    
 The electrophysiological studies discussed above from our laboratory 
confirm the activity of Kv7 currents in ASMCs. They also showed that Kv7 currents 
can be suppressed by Gq/11-coupled receptor agonists similar to other smooth 
muscle cells. These results suggest that common signal transduction intermediates 
are likely to be involved in the mechanism of suppression of Kv7 currents by Gq/11-
coupled receptor agonists in ASMCs. Following histamine and or methacholine- 
induced suppression of Kv7 currents, the current amplitude was restored to near 
control values by flupirtine, indicating that flupirtine may either act by reversing the 
blockage of Kv7 currents by bronchoconstrictor agonists, or by simply enhancing 
the unblocked Kv7 currents. In either case, Kv7 channel activators show 
tremendous potential in antagonizing the effect of bronchoconstrictor agonists on 
airways in this preliminary study. 
Summary 
 Asthma is a disease characterized by constriction of ASMCs with AHR being 
an integral component of its complex pathophysiology.  Regulation of calcium 
signaling is considered to be the key in understanding ASMCs contraction and 
19 
relaxation. Influx of calcium from extracellular space is an important event that 
leads to contraction of ASMCs. Several bronchoconstrictor agonists are known to 
cause membrane depolarization that can lead to the opening of L-type VSCC, which 
are considered to be the major contributors to bronchoconstrictor-agonist mediated 
influx of calcium. Our laboratory has previously shown that Gq/11-coupled receptor 
vasoconstrictor hormone AVP, in low, physiologically relevant concentration acts by 
suppressing the activity of Kv7 channels, thereby leading to membrane 
depolarization and activation of L-type VSCC. In other words, Kv7 channels are 
determinants of resting membrane potential in VSMCs and their suppression can 
lead to membrane depolarization.  We envision a similar role for Kv7 channels in 
ASMCs, wherein their activity is suppressed by bronchoconstrictor agonists to 
mediate bronchoconstriction. However, expression and function of Kv7 channels in 
ASMCs was largely unknown. The research presented in this thesis focuses on 
detecting expression of various Kv7 channel subtypes in ASMCs, comparing their 
expression pattern in normal and diseased airways, and determining the functional 
role they play in airway modulation.  The electrophysiological studies that were 
conducted in parallel to this investigation have detected Kv7 currents in guinea pig 
and human ASMCs. The Kv7 currents in guinea pig ASMCs are suppressed by 
bronchoconstrictor agonists and were shown to be restored to near control levels 
upon treatment with Kv7 channel activators. The expression and ex-vivo functional 
studies presented in this thesis evaluate the potential of targeting Kv7 channels as 





Airway Hyperresponsiveness (AHR) is the characteristic feature of asthma 
pathophysiology, the molecular mechanisms of which are poorly understood. The 
overarching goal of the research presented in this thesis is to elucidate the 
mechanisms underlying AHR in asthma. This will not only help us gain a better 
insight into the pathophysiology of asthma, but may further lead to the discovery of 
novel and improved therapeutic agents. The primary objectives of this research are to 
investigate the role played by a Kv7 K+ channels in pathophysiology of AHR, and to 
explore the regulation of Kv7 channels as a novel therapeutic strategy in treatment of 
asthma. 
Rationale 
Although Kv7 channels were considered to be primarily expressed in 
neuronal cells, recent findings have revealed their expression in different excitable 
cells like cardiac myocytes and vascular smooth muscle cells (VSMCs) (Joshi et al. 
2006; Yeung et al. 2007; Brueggemann et al. 2007; Greenwood et al. 2009).  The key 
role attributed to Kv7 channels is the prevention of membrane depolarization by 
stabilizing the negative membrane potentials on these cells (Mackie et al. 2008b). 
Mutations in KCNQ genes encoding Kv7 channels have been shown to be linked to 
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various high-impact diseases like cardiac arrhythmias, epilepsy and deafness. As 
discussed in chapter one, our laboratory has discovered that Gq/11-coupled hormone 
[Arg8]vasopressin (AVP) elicits its vasoconstrictor action by inhibiting the activity of 
Kv7.5 channels in VSMCs via a PKC-dependent pathway (Brueggemann et al. 2007).  
Findings from our laboratory have further suggested that the Kv7 channel activators 
that are used clinically in management of neuronal disorders are effective in 
reversing the vasoconstrictor effect of AVP in VSMCs (Brueggemann et al. 2007; 
Mackie et al. 2008a).  The crucial role played by Kv7 channels in VSMCs and other 
excitable cells has motivated us to explore the significance of these channels in 
airway smooth muscle cells (ASMCs) excitability.  
Hypothesis 
Our main hypothesis is that Kv7 channels play a critical role in maintaining 
negative resting membrane voltages in ASMCs similar to other excitable cells, and 
that bronchoconstrictor agonists promote ASMC contraction and airway narrowing 
by suppressing the activity of Kv7 channels (Figure 9). We further hypothesize that 
Kv7 channel activators will reverse the bronchoconstrictor agonist-mediated ASMC 
contraction by restoring the activity of Kv7 channels.  
  
Figure 9: Hypothesis for the research presented in this thesis. 











These hypotheses provide a pathophysiological basis for AHR in asthma and 
will be tested by studies proposed in following two specific aims. 
Specific Aim 1 
Identify the Kv7 channel-subtypes expressed and compare their expression 
profiles in normal and allergen-sensitized guinea pig ASMCs. 
Specific Aim 2  
Evaluate the efficacy of Kv7 channel activators in relaxation of allergen-
sensitized guinea pig airways pre-constricted with bronchoconstrictor agonists 
using precision-cut lung slices (PCLS).  
Significance  
Successful completion of this research will identify the subtypes of Kv7 
channels that are predominantly expressed in normal and allergen-sensitized 
guinea pig airways. The differences, if any, in the expression pattern of various 
subtypes in normal and asthmatic ASMCs will provide us with important leads in 
determining the role played by Kv7 channels in pathophysiology of AHR. The PCLS 
studies will provide us with information on effectiveness of Kv7 channel activators 
in relaxation of bronchoconstrictor agonist-mediated airway constriction. Overall, 
the proposed research will not only probe into the unknown mechanisms for AHR in 
asthma, but it is also likely to lead in to identification and pharmacological 





GUINEA PIG MODEL OF AIRWAY HYPERRESPONSIVENESS 
Asthma is a prime example of a complex and multifactorial disease. It is also 
a disease that is unique to humans as none of the commonly employed laboratory 
animals naturally acquire the asthma-like syndrome that is endemic in humans.  
Asthma, therefore, poses a considerable challenge for development of animal 
models with symptoms that can accurately mimic those observed in human asthma. 
Despite inherent challenges, various animal models of asthma have been developed 
over the years that mimic several important symptoms observed in human asthma. 
So far, asthma-like symptoms have been reproduced in animals like mice, rats, 
guinea pigs, ferrets, dogs, sheep, monkeys and horses. However, each animal model 
has its own advantages and disadvantages (Canning 2003).  
Mice offer several advantages in the study of asthma compared to other 
animals.  Firstly, numerous inbred strains are available for mice compared to other 
species. A detailed understanding of mouse genetics arguably improves its 
suitability for employment of transgenic technology (Elias et al. 2003).  Moreover, 
numerous commercially available mouse-specific probes, immunological reagents, 
growth factors, and cell surface markers are available for mice. Importantly, mice 
have IgE as the primary allergic immunoglobulin similar to that found in humans. 




and humans that do not favor a straightforward extrapolation of asthma related 
findings to humans. For example, unlike humans, mice do not exhibit spontaneous 
AHR and have limited airway musculature (Shin et al. 2009). Additionally, human 
airways have a larger diameter compared to mouse airways and different airway 
diameter respond differently. Therefore, transposing data from mice to human 
could be misleading (Kips et al. 2003). In fact it has been shown that human airway 
responses to agonists are not similar to the responses in mouse airways (Held et al 
1999) .These factors limit the use of mice as an animal model of asthma. 
Guinea pigs are the animals most frequently used to model anaphylactic 
(early, immediate type) bronchoconstriction. Guinea-pigs are readily sensitized to 
ovalbumin (OVA) (Sundstrom et al. 2003) and it is easy to elicit a response to a 
challenge that is similar to an asthmatic phenotype involving increased airway 
responsiveness (Pretolani et al. 1996). To evaluate if they are a good model for 
human airways, the response of isolated guinea-pig airways to pharmacological 
agonists has been compared directly with humans (Muccitelli et al. 1987). This 
study revealed that histamine and methacholine had comparable EC50 values and 
showed similar maximal responses in both guinea pig trachea and human bronchus. 
Notably, allergen-induced bronchoconstriction in guinea pigs and human bronchial 
asthma have several features in common, and hence many important findings in 
human asthma pathophysiology have emerged from the guinea pig model of asthma 
(Szeleny I. 2000). Additionally, the potencies and efficacies of agonists and 




(Canning et al. 2008). However, the guinea pig model also suffers from a few 
disadvantages. The major anaphylactic immunoglobulin in guinea pigs is IgG1 as 
compared to IgE in humans. Furthermore, there is a lack of guinea pig-specific 
immunological and biochemical reagents, and there is also a shortage of inbred 
strains. Therefore, genetic influences on susceptibility to sensitization and 
development of airway disease are difficult to investigate in guinea pigs (Shin et al. 
2009).  However, weighing the successes of the guinea pig model in studying asthma 
and asthma-related diseases, as well as the similarity to human airways in 
responses to various bronchoconstrictor agonists, justifies our use of this animal 
model for the studies presented in this thesis. 
Animal Welfare and Housing 
Male Hartley guinea pigs (250-350gm) were purchased from Elm Hill/Cady 
Ridge Farms, and housed in a plexiglass cage (2 animals per cage) and fed ad libitum 
in a regular 12-h dark/light cycle. All procedures described in this study were 
approved by the Institutional Animal Care and Use Committee, Loyola University 
Medical Center, Maywood, IL and were conducted in accordance with the Guide for 
the Care and Use of Laboratory Animals (1996, National Academy of Sciences, 
Washington D.C.) 
Induction of AHR in guinea pigs 
The stepwise protocol for induction of AHR in guinea pigs is as depicted in Figure 




injections of ovalbumin (OVA) (100 µg OVA and 100 mg aluminium hydroxide in 1 
mL saline) or saline alone (control) on days 1, 3 and 5 (Mazzone SB et al. 2002).  
 
Figure 10: Flow chart depicting various treatment stages in the development of guinea pig model of 
airway disease.  
 After a subsequent 2-week sensitization period, the animals were placed in a 
cylindrical Plexiglas chamber where they were observed for at least 1 minute and 
then exposed to a nebulized solution of OVA. This protocol was subjected to 
optimization with different concentrations of OVA and duration of its exposure (see 
troubleshooting section below). Finally, the animals were exposed to an optimized 
concentration (5 mg/ml) of OVA in saline for 30 min using a commercial DeVilbiss 
nebulizer with a constant pressure at ~0.3 ml/min (Smith et al. 2005). This protocol 
was repeated at one day intervals for a total of 3 trials. Two days prior to the 
exposure of aerosolized ovalbumin, the animals were acclimatized to fine mist of 
saline under the same conditions.  According to the published studies, this protocol 
Day 1,3,5 i.p injection of ovalbumin (100 µg/mL 
OVA and 100 mg Al(OH)3 in saline)
young male (250-350 gm)
Day 6-18 2 week sensitization period
Day 19 exposed to fine mist of 
ovalbumin (5 mg/ml for 30 min) or saline
Day 20,21
protocol repeated at 1 




should induce asthma attacks in a fairly uniform fashion. Ottenberg and coworkers 
list the sequence of respiratory signs observed in this model as follows: “rapid 
breathing, restlessness, chewing, ruffling of the fur, then labored breathing with the 
use of accessory muscles of respiration, prolonged expiration, gasping, coughing, 
dilation of alae nasi, and finally cyanosis and convulsion” (Ottenberg et al. 1958). 
The allergen-sensitized guinea pigs were observed for measurement of the time of 
onset of respiratory attack. The attack was characterized by the use of accessory 
muscles for respiration, gasping, coughing, and pronounced respiratory distress. 
Animals were closely monitored and any symptoms observed were recorded.   
The animals were staggered in such a way that one animal was injected every 
week starting with either saline control or allergen sensitized animal in the first 
week and reversing the order with the next set of animals. The treatments and 
schedules involved three i.p injections (saline or OVA) on Monday (Day 1), 
Wednesday (Day 3) and Friday (Day 5) followed by exposure to aerosolized OVA on 
Friday (Day 19), Saturday (Day 20) and Sunday (Day 21), i.e two weeks following 
the last injection . The animals were then euthanized on the following Monday (Day 
22) and the airway smooth muscle cells were isolated (see chapter 4 for detailed 
procedures) from the upper part of the trachea for the expression studies. One half 
of the surgically excised lung was inflated with agarose for preparation of slices (see 
chapter 5 for detailed procedures). The other half of the lung was reserved to isolate 






Our initial use of 10 µg/ml ovalbumin concentration to challenge guinea pig 
following the 2 week sensitization period did not show the expected symptoms of 
airway disease. A previous study using different concentration of ovalbumin (10 
µg/ml, 100 µg/ml, 1 mg/ml, 5 mg/ml and 10 mg/ml) on five successive days 
reported that 1mg/ml OVA induced symptoms like labored breathing, coughing and 
rubbing of nose (Boichot et al. 1991). Based on this report, we modified our protocol 
for OVA challenge, by increasing the aerosolized OVA concentration from 10 µg/ml 
to 5 mg/ml. This concentration developed some of the symptoms like labored 
breathing and gasping through the end of 15 minutes trial in allergen-sensitized 
guinea pigs, but not in the saline control animals as expected. However, the most 
severe symptoms (like prolonged expiration, coughing, dilation of alae nasi, 
sneezing cyanosis and convulsion) were not observed in these animals. Based on 
these observations and some additional published studies, we decided to prolong 
the exposure time to 30 minutes (Lai et al. 2003; Ram et al. 2003).  
Summary 
 In total, 4 saline control and 4 allergen treated guinea pigs were monitored in 
a staggered fashion. The protocol for induction of AHR was revised (change in the 
concentration of OVA challenge and exposure time) based on the observations made 
during these studies. Optimization in the protocol led to the observation of some 
important symptoms like labored breathing and gasping in the allergen sensitized 
animals but not in the saline control animals.  
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CHAPTER 4 
EXPRESSION OF Kv7 CHANNELS IN NORMAL AND ASTHAMATIC AIRWAYS 
As discussed in chapter 1, Kv7 channel subtypes are found to be expressed in 
a variety of excitable cells such as neuronal cells and vascular smooth muscle cells 
(VSMCs), and play a pivotal role in controlling membrane excitability in these cells. 
However, to our knowledge the expression of Kv7 channels in airway smooth 
muscle cells (ASMCs) was previously unknown. Therefore, in order to investigate 
the role of Kv7 channels in airway smooth muscle cells (ASMCs), it was essential to 
know whether these channels are expressed in airways in the first place. Secondly, it 
is known that particular subtypes of Kv7 channels are predominantly expressed in 
specific tissues, for example, Kv7.1 subtype has been found to be expressed largely 
in cardiac myocytes, whereas Kv7.2–7.5 have been found to be expressed mainly in 
neuronal cells (Jentsch 2000; Schroeder et al. 2000a).  So if Kv7 channels are 
expressed in ASMCs, then we were also interested in measuring expression of 
different subtypes of Kv7 channels in ASMCs. Finally, to achieve our objective of 
exploring the role played by Kv7 channels in AHR, it is important to study and 
compare the expression levels of Kv7 channels in normal and asthmatic airways. 
Therefore, quantitative real-time reverse transcriptase-polymerase chain reaction 
(qRT-PCR) studies were conducted in ASMCs obtained from normal, saline-control 
and allergen-sensitized guinea pigs using primers specific for guinea pig KCNQ1-5. 
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The availability of human tissues also led us to identify and measure the expression 
levels of different Kv7 subtypes in human ASMCs (studies not a part of proposed 
research). The use of human tissues for this study was reviewed and approved by 
the Loyola University Chicago Institutional Review Board for the Protection of 
Human Subjects. 
Step 1: Isolation of Airway Smooth Muscle Cells (ASMCs) 
The ASMCs from normal, saline-control and allergen-sensitized guinea pigs 
were isolated using a method reported by Janssen and Sims (Figure 11) (Janssen et 
al. 1992).  In short, connective tissue, vasculature and innervation were removed 
from primary and secondary bronchi. Bronchial segments 3-5 mm in length were 
then transferred to ice cold physiological saline solution (PSS) containing in mM: 
140 NaCl, 5.36 KCl, 0.34 Na2HPO4, 0.44 KH2PO4, 1.2 MgCl2, 0.05 CaCl2, 10 HEPES, 10 
D-Glucose, pH adjusted to 7.2 with NaOH on ice, 298 mOsm/L. The segments were 
then cut open and the epithelium was removed using a cotton-tipped applicator. 
Each bronchial segment was cut into strips approximately 1 mm wide. The 
bronchial strips were then transferred into PSS (pH adjusted to 7.2 with NaOH at 37 
°C) supplemented with BSA (1 mg/ml), collagenase Type VIII (400 units/ml), papain 
(30 units/ml), and DL-dithiothreitol (1 mM). The strips were then incubated for 45-
60 min at 37 °C. After enzymatic digestion, the tissue was washed 3-5 times with ice 
cold PSS and gently triturated with a fire-polished Pasteur pipette to release 
individual myocytes. After trituration of the tissue, remaining undigested pieces 
were removed and ASMCs were pelleted by centrifugation (5 min at 2000 g). The 
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cells were then stored at -20 °C in a Qiagen RNAeasy plusTM lysis buffer (350 µL lysis 
buffer with 1 % β-mercaptoethanol) and used as required for qRT-PCR studies. 
 
Figure 11: stepwise procedure for isolation of guinea pig ASMCs.  
Human tracheal tissue was obtained from discarded lung transplant donor 
tissue and trachealis muscles were dissected from the trachea in ice cold dissecting 
solution and cut into strips approximately 2 mm in diameter. Strips of muscle were 
then transferred to ice cold PSS and then into PSS at 37 C (pH adjusted to 7.2 with 
NaOH at 37 C) supplemented with BSA (1mg/ml; fraction V, Roche Diagnostics 
USA), collagenase Type VIII (950 units/ml; Sigma), papain (38 units/ml; 
Worthington), and DL-dithiothreitol (1 mM; Sigma). The strips were then incubated 
for 45 min at 37 C. After enzymatic digestion, the tissue was washed 3-5 times with 
ice cold PSS and gently triturated to release individual myocytes.  
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Step 2: qRT-PCR studies in (normal, saline-control and allergen-sensitized) 
guinea pig ASMCs and normal human trachealis muscles 
qRT-PCR was used to determine the expression of KCNQ1–5 in guinea pig 
ASMCs and human trachealis muscle.  ASMCs were isolated as described above from 
smooth muscle dissected free from the entire trachea. The cells (or trachealis 
muscles) so obtained were disrupted and homogenized using a Polytron 
homogenizer for 30 Seconds. Total RNA was extracted from ASMCs by use of RNeasy 
Plus Mini Kit (Qiagen, Valencia, CA). The RNA purified with a RNeasy silica-
membrane method, is expected to remove most of the genomic DNA contamination 
efficiently. The RNA so obtained was not further treated with DNAase. RNA was 
quantified using a NanoDrop spectrophotometer, and the mRNA was reverse 
transcribed with a Bio-Rad iScriptTM cDNA synthesis kit. The cDNA thus obtained 
was amplified in a qRT-PCR reaction by using primers specific for guinea pig 
KCNQ1–3, 5 (Navarro-López et al. 2009) and KCNQ4 (Liang et al. 2006) (Table 1). 
Quantitative expression was performed with Applied Biosystems 7300 Gene 
Expression System in 25 µl reactions consisting of 12.5 µl MaximaTM SYBR 
Green/ROX qPCR Master Mix (Fermentas, Burlington, Ontario, Canada), cDNA 
derived from 25–250 ng mRNA, and 5 pmol each primer. Cycle parameters were 
typically 95°C for 15 s, followed by 60°C for 30 s (40 cycles), and followed by a 
dissociation step to confirm a single PCR product. Specificity of the PCR primers was 
also verified by DNA sequencing. Standard curves were plotted by 10-fold serial 
dilution of known amounts of cDNA for each target. Primer efficiencies were 
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determined from the slope of the standard curve dilution series for each of the 
KCNQ targets, by using the formula Efficiency = 1+10(1/slope). The correlation 
coefficients for all standard curves were >0.99, and slope values gave efficiencies 
90% in all cases. The target copy number in a sample was estimated by relating the 
PCR threshold cycle to the known target value on the standard curve. The mRNA 
levels of KCNQ1–5 were averaged from four male guinea pigs (250–350 g) with each 
reaction performed in duplicate. RNA extracted from one guinea pig ASMC sample 
was reverse transcribed as described above for end point PCR to confirm PCR 
product sizes for each primer pair. cDNA was amplified by using Platinum Taq PCR 
Mix (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol and 
conventional PCR cycle parameters of 95°C for 1 min, 50°C for 1 min (30 cycles), and 
final extension at 72°C for 5 min. The PCR products were separated by agarose gel 
electrophoresis and the gel was visualized and imaged by use of a BioImaging 
System (UVP, Upland, CA).  
Human trachealis RNA was extracted from human donor lung trachealis 
muscle (cut into 2 mm - 5 mm pieces; 4–5 pieces per human sample) by the acid-
guanidinium-phenol extraction method (Chomczynski et al. 1987). Reverse 
transcription was carried out as above, and qRT-PCR was performed with primer 
pairs specific for human KCNQ genes (Ng et al. 2011) (Table 2). To determine if the 
RNA sample was contaminated with genomic DNA we included a no reverse 
transcriptase control in the real time PCR. The PCR end products (plus/minus RT) 
were than allowed to run on an agarose gel. All the minus RT samples except KCNQ4 
34 
 
showed absence of band confirming that the RNA samples were free of genomic 
DNA. However, the RNA samples were not treated with DNase for further 
purification. Each reaction was performed in triplicate for at least four individuals, 
and KCNQ1–5 transcript copy numbers were estimated as described above for 
guinea pig, by comparing to standard curves constructed for each of the human 
KCNQ gene targets. 
 
 
















Table 1: Guinea Pig Primers




















Results   
Expression of multiple Kv7 channel subtypes in normal guinea pig and human ASMCs: 
The qRT-PCR expression studies using primers specific for guinea pig and human 
KCNQ1-5 revealed expression of multiple subtypes of Kv7 channels in normal 
guinea pig and human ASMCs. The expression pattern in normal guinea pig ASMCs 
was as follows: KCNQ2>KCNQ5>KCNQ4>KCNQ3>>KCNQ1 (Figure 12A). The 
ASMCs from human trachealis muscles revealed a more variable pattern of 
expression, with abundant expression of KCNQ1, no detectable expression of KCNQ2 
and KCNQ3, and modest expression of KCNQ4 and KCNQ5 (Figure 12B). The 
products were also confirmed by sequencing.  
 
Figure 12: Multiple KCNQ subtypes are expressed in guinea pig and human airway smooth 
muscle cells (ASMCs).  Expression levels of mRNAs for KCNQ1-5 were estimated using quantitative 
real time RT-PCR in guinea pig airway myocytes (A) and human trachealis muscle (B). Average ng 
target (normalized to ng input of RNA) mRNA ± SEM from n=4 guinea pigs and from n=4 human 





























































Figure 13: Immunohistochemistry studies supporting expression of Kv7 channels in airways. 
Immunostaining of guinea pig trachealis myocytes (C) and human trachealis myocytes (D) stained 
with anti-Kv7.1–7.5 antibodies (top rows); and stained with Kv7.2 and Kv7.3 antibodies preincubated 
with the corresponding blocking peptide (anti-Kv7.2 BP; anti-Kv7.3 BP) (bottom rows). Cells 
processed for imaging without primary antibody (1° control) show no detectible fluorescence in 
ASMCs at the same gain and intensity settings (right). (Brueggemann LI, Kakad PP, et al. (2012) Am J 
Physiol Lung Cell Mol Physiol 302(1):L120-132). 
The expression of multiple Kv7 channel subtypes in guinea pig and human 
ASMCs was also supported by immunohistochemistry studies (outside the scope of 
proposed studies; carried out by Dr. L. Brueggemann) (Figure 13). The 
immunohistochemistry studies are not quantitative and hence we did not attempt to 
compare the expression levels in guinea pig and human ASMCs. Our sole objective 
was to confirm the expression of translational gene products. Our studies thus 
provide the first evidence of expression of Kv7 channels in guinea pig and human 
anti Kv7.1 anti Kv7.2 anti Kv7.3 anti Kv7.4 anti Kv7.5 -1º control
anti Kv7.2+BP anti Kv7.3+BP
Guinea pig
-1º controlanti Kv7.1 anti Kv7.2 anti Kv7.3 anti Kv7.4 anti Kv7.5






airways, thus paving the path for further exploration of their role in AHR. Our next 
step was to compare the expression pattern of different Kv7 channel subtypes in 




























Figure 14: Comparing expression pattern of different Kv7 channel subtypes in saline-control 
and allergen-sensitized guinea pig ASMCs.  Expression levels of mRNAs for KCNQ1-5 were 
estimated using quantitative real time RT-PCR in saline-control guinea pig ASMCs ( ), and allergen-
sensitized guinea pig ASMCs ( ). Average ng target mRNA ± SEM from n=4 saline-control guinea pig 
ASMCs and n=4 allergen-sensitized guinea pig ASMCs. 
Differences in expression pattern of Kv7 channel subtypes in saline-control and 
allergen-sensitized guinea pig ASMCs: In these preliminary studies comparing 
expression of different Kv7 channel subtypes in saline-control and allergen-
sensitized ASMCs (Figure 14), an interesting trend was observed: expression of all 
KCNQ channel subtypes was found to be decreased in allergen-sensitized guinea pig 
ASMCs. In these initial studies, ASMCs from four saline-control and allergen-
sensitized animals were used. The decrease in expression of Kv7 channel subtypes 
however, was not statistically significant, due to a variety of reasons. Firstly, the 
number of animals used in the study was not sufficient (power of comparison below 
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0.80) to obtain significant results due to high variability inherent to animal studies. 
Secondly, the four allergen-sensitized guinea pigs used for isolation of ASMCs 
received different amount of allergen treatment as these animals were mostly from 
the optimization studies we performed in the animal model preparation. Therefore, 
these studies need to be repeated with ASMCs from allergen-sensitized guinea pigs 
receiving now-optimized allergen treatment. However, if a decreased expression of 
KCNQ subtypes in allergen-sensitized guinea pigs is reproducibly observed, this will 
have important implication for our understanding of the etiology of AHR.  Also, the 
reason for differences in the expression pattern of Kv7 channel subtypes between 
saline-treated and normal guinea pigs is unclear. This could be possibly attributed 
to the inherent inter-animal variability. We expect to see diminished variability as 
the number of animals is increased in our future studies. 
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CHAPTER 5 
FUNCTIONAL ROLE OF Kv7 CHANNELS IN AIRWAYS 
Our qRT-PCR studies not only revealed the expression of different Kv7 
channel subtypes in guinea pig and human ASMCs for the first time, but also 
provided preliminary evidence that the expression of different subtypes of Kv7 
channels is decreased in allergen-sensitized guinea pig airways. These results 
support our hypothesis that Kv7 channels have an important role to play in normal 
airway function, which is affected in asthmatic airways. Therefore, our next goal was 
to determine the functional relevance of these channels in normal and diseased 
airways. There are several in vitro models such as the tracheal or bronchial rings 
and parenchymal smooth muscle strips, that have been used to study the airway 
function. However, precision-cut lung slices or PCLS offer many advantages 
(Henjakovic et al. 2008; Liberati et al. 2010).  Using PCLS, functional airway 
narrowing responses and the concentration-dependent responses to 
bronchoconstrictors and bronchodilators can be directly observed and recorded 
with a high degree of accuracy. PCLS preparations maintain cell–cell and cell–matrix 
relationships reproducing many properties and functions of the whole organs, 
therefore serving as an excellent ex vivo alternative for in vivo studies. Moreover, 
more than 30 lung slices can be prepared from one guinea pig lung and each animal 
can serve as its own internal control. Therefore, this method provides a 
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greater throughput for evaluating multiple drugs using fewer animals. However, a 
major challenge for PCLS studies specific to guinea pig preparations is post mortem 
airway constriction (Lai et al. 1984a). The cause of this post mortem constriction is 
not fully understood but it is attributed to the release of substance P from sensory 
neurons (Lai et al. 1984b).  Ressmeyer and coworkers have reported a solution for 
post mortem constriction by introducing isoproterenol in the media used for PCLS 
preparation. It is suggested that once the PCLS preparation is complete, 
isoproterenol use be discontinued. The isoproterenol effect is not sustained after 
discontinuation and the slices respond normally to various treatments (Ressmeyer 
et al. 2006). 
 Preparation of Precision-Cut Lung Slices (PCLS) 
Chemicals: Histamine, methacholine(acetyl-β-methylcholine chloride), ovalbumin 
and aluminium hydroxide required for PCLS studies were purchased from Sigma-
Aldrich (St. Louis, MO). Retigabine dihydrochloride was purchased from LGM 
Pharma (Boca Raton, FL). XE-991 dihydrochloride was from Ascent Scientific 
(Princeton, NJ). Low melting point agarose was from GIBCO® (Invitrogen Corp, 
Carlsbad, CA). Drugs were diluted as needed in the control vehicle (2 mM Ca+2 
Physiological Saline Solution (PSS)) used for the precision-cut lung slices. Drugs 
were used in a concentrations ranging from 1 nM to 10 µM. 
Protocol: Post euthanasia (sodium pentobarbital overdose), a thoracotomy was 
performed and the heart was excised to expose the bronchi. The lower half of the 
trachea was cut and cannulated with a 1/16” polyethylene tube connector attached 
to a 3-way stop-cock. One of the bronchi was tied off and that was reserved for 
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electrophysiological studies. The cannulated tissue was then placed into a glass 
beaker with mHBSS (modified-Hank’s Balanced Salt Solution (mM): NaCl 137.9, KCl 
5.33, CaCl2 1.26, MgCl2 0.49, MgSO4 0.41, HEPES 20, KH2PO4 0.44, Na2HPO4 0.34, D-
glucose 5, pH 7.4-NaOH at 37°C, 298-300 mOsm) preheated to 37°C in a water bath. 
With a 10 mL syringe attached to one inlet, the lung was deflated. On the another 
inlet of the stopcock there was a 10 mL syringe filled with low-temperature-melting 
Type IX-A agarose (2 % in mHBSS supplemented with 20 mM HEPES). The agarose 
solution also contained isoproterenol in varying doses (see troubleshooting section) 
at 37 °C. The lung was inflated by injecting the warm agarose solution. After 
inflating the lungs with warm agarose, 5 ml of air was injected using a second 
syringe to push agarose into the alveoli from the airways.  The inflated lungs were 
then placed into a glass beaker containing ice cold mHBSS (pH 7.4 at 4°C) and 
allowed to cool on ice for 30 minutes to solidify the agarose. The non-inflated lobe 
was cut and used for isolation of airway smooth muscle cells (as discussed in 
chapter 3). Precision-cut lung slices were made by use of a Leica VT 1200S 
vibratome, while maintaining the lung at 4 °C. Lung slices (350 μm thick) containing 
cross sections of 0.05– 0.5 mm in diameter, were incubated for 3 h in serum-free F-
12/ DMEM (Dulbecco's Modified Eagle Medium) tissue culture medium containing 1 
µM isoproterenol, supplemented with ITS (Insulin-Transferrin-Selenium, Mediatech, 
Manassas, VA) and antibiotics at 37°C under 5% CO2. Medium was changed after 
every 30 minutes for 3 h. After 3 h, the slices were transferred to the same medium 
but without isoproterenol. Lung slices generally remained viable for at least 4 days. 
Slices containing airways were used only if 1) the airway was approximately 
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circular; 2) beating cilia were observed (indicating an intact epithelium) and; 3) the 
airway wall and all parenchymal attachments were intact. The selected lung slice 
was then transferred into a 35 mm tissue culture dish onto a 25 mm diameter round 
glass coverslip (sterilized by dipping in 100% ethanol and flame dried). The dish  
contained 1 ml of 2 mM Ca2+ PSS (control medium (mM): 140 NaCl, 5.36 KCl, 1.2 
MgCl2, 2 CaCl2, 10 HEPES, 10 D-glucose, pH 7.3, 298 mosmol/l).  
Measurement of airway diameter: Vacuum grease was applied to the groove of a 
customized recording chamber.  A coverslip with a PCLS was positioned evenly into 
the groove of the chamber. A silicon ring was gently placed on the coverslip in order 
to avoid any leak.  Finally, a platinum weight was placed on the slice so as to hold 
the slice in position without blocking the view of the airway. The chamber was then 
filled with 1 ml of the control medium. The glass bottom of the chamber was cleaned 
with an alcohol soaked Kim-wipe®.  The lung slice, mounted in the perfusion 
chamber was then placed on the stage of an inverted microscope (Olympus IX-71) 
and visualized via a 10X objective.  A cross section of a small bronchiole (0.05–1.5 
mm in diameter) was positioned in the center of the microscopic field and the lung 
slice was then equilibrated in control medium at room temperature for at least 30 
min. Control medium, plus or minus drugs, was continuously superfused over the 
lung slice via a gravity-fed perfusion system at a rate of ~5 ml/min, controlled by a 
common flow regulator. Experiments were conducted at room temperature. The 
focus and light intensity was adjusted to see the clear image. The region of interest 
(ROI) for the measurement was selected (red outline). The threshold range that 
identifies the object in green for measurement was then selected (Figure 15). 
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Images were captured with a 12-bit digital camera (Hamamatsu Orca) at 5-s 
intervals. Luminal area was measured by image analysis using Simple-PCI software 
(Hamamatsu, Sewickley, PA). Summarized measurements of luminal area of the 
airway in each experiment represent the average for the last 1 minute of drug 
application or washout (total 12 measurements in each case).  
 
 
Figure 15: Image demonstrating luminal area measurement of PCLS preparation. A cross 
section of a small bronchiole (0.05–1.5 mm in diameter) is positioned in the center of the 
microscopic field. The threshold range that identifies the object for measurement in green is selected. 
Images are captured at 5-s intervals. 
 
 To obtain dose-response curves for bronchoconstrictor agoinsts (histamine 
and methacholine) in saline-control and allergen-sensitized airways, the PCLS 
preparations from these animals were treated with agonist concentrations ranging 
from 1 nM to 30 µM. The dose-response studies were repeated in PCLS from 
multiple animals and the data was then plotted as normalized area versus logarithm 
of agonist concentration using Graph Pad Prism software. The half-maximal 
effective concentration (EC50) was determined by fitting the data to five-parameter, 




Following the procedure reported by Ressemeyer and coworkers  to prevent 
post mortem constriction,  1 µM isoproterenol in agarose solution was used 
(Ressemeyer et al. 2006). However, the slices using this protocol did not respond to 
any of the agonists tested and instead constricted or dilated spontaneously in the 
control medium independently of the drug treatment.  After a few repetitions with 
similar outcome, we decided to omit isoproterenol from our experiments. This, 
however, did not solve the problem. The slices obtained from these lungs did not 
respond to any concentration of agonist. Instead a very stable baseline recording 
was obtained independently of the treatment. A lower concentration of 
isoproterenol (100 nM) in agarose was also tested. However, the problem persisted 
despite use of the lower isoproterenol concentration. 
Finally, we went back to the original protocol, using 1 µM isoproterenol in 2 
% agarose solution to inflate the lungs. However, this time the slices were 
maintained in medium containing 1 µM isoproterenol after preparation. This solved 
the problem of post mortem constriction as well as the unusual behavior exhibited 
by the guinea pig lung slices in the earlier studies.  
Results 
The physiological relevance of functional Kv7 channels in guinea pig airways was 
investigated using PCLS studies. Before beginning our planned pharmacological 
studies, we wanted to confirm the hypersensitivity of actively sensitized airways 
obtained from the allergen-sensitized guinea pig model. This was done by 
challenging these actively sensitized airways with ovalbumin (passive challenge). 
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Application of 1 µg/ml ovalbumin alone completely closed the airways, providing 
strong evidence that the airways of OVA-treated animals were indeed 
hypersensitized. As observed from the time course (Figure 15), the airways started 
to relax while still in ovalbumin, this could be due to the depletion of the agonist 
stores (methacoline, histamine), which cannot be resynthesized in the ex vivo model 
of PCLS. 
 
Figure 16: Passive sensitization of airway from guinea pig model of AHR using ovalbumin 
(OVA). Representative time course after treatment with 1 ug/mL OVA to PCLS preparations obtained 
from actively sensitized guinea pig airways. 
Increased sensitivity of allergen-sensitized airways to bronchoconstrictor 
agonists: Our next goal was to evaluate the differences in response of saline-control 
and allergen-sensitized airways to the bronchoconstrictor agonists, histamine and 
methacholine. We expected increased sensitivity of allergen-sensitized airways to 
bronchoconstrictor agonists. As expected, the allergen-sensitive airways showed 
clear and distinct hyperresponsiveness to both histamine and methacholine. Our 
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next step was to determine the half-maximal effective concentrations (EC50) for 
these agonists in both saline-control and allergen-sensitized airways. The dose-
response curves for histamine (Figure 16) and methacholine (Figure 17), were 
determined in saline-control and allergen-sensitized airways. As expected there was 
shift in the dose-response curve toward left for allergen-sensitized airways 
indicating increased sensitivity to bronchoconstrictor agonists. The observed EC50 
value of 204.5 nM obtained from the dose-response curve of histamine in saline-
control guinea pig airways was in a very good agreement with literature reported 
value of 217 nM in normal guinea pig airways (Ressemeyer et al. 2006). 
Importantly, there was ~4.5 fold decrease in the EC50 value (45.9 nM) observed in 
allergen-sensitized airways thus providing clear evidence that AHR has been 
induced in the guinea pig model. Dose-response curve for methacholine showed 
~2.5 fold decrease in the EC50 value in allergen-sensitized airways (28.7 nM) 
compared to saline-control guinea pigs airways (72.0 nM). Along with an increase in 
sensitivity to histamine and methacholine in allergen-sensitized airways, a 
considerable increase in Emax (maximal effect) was observed with both 























      
  
 
























Figure 17: Dose-response curves for histamine in PCLS preparations from saline-control and 
allergen-sensitized guinea pig airways. A: representative images showing change in luminal area 
of PCLS preparations after treatment with increasing concentrations of histamine (H) in saline-
control (top) and allergen-sensitized (bottom) airways. B: corresponding representative time course 
of changes in luminal area of the same PCLS preparations in saline-control (left) and allergen-
sensitized (right) airways.  C: Dose-response curve obtained by plotting the normalized luminal area 
versus logarithm of histamine concentration in saline-control ( , n = 3) and allergen-sensitized (∎, n 
= 2) airways. Half-maximal effective concentration (EC50) values were obtained by fitting the data to 
the five-parameter, variable slope equation using GraphPad® Prism software (La Jolla, CA). Dose-
response curve for histamine in saline-control guinea pigs gave an EC50 = 204.5 nM that is in very 
good agreement with literature reported value of 217 nM (Ressemeyer et al. 2006). The EC50 of 
histamine in allergen-sensitized guinea pigs was calculated to be 45.9 nM.  
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Figure 18: Dose-response curves for methacholine (MC) in PCLS preparations from saline-
control and allergen-sensitized guinea pig airways. A: representative images showing change in 
luminal area of PCLS preparations after treatment with increasing concentrations of MC in saline-
control (top) and allergen-sensitized (bottom) airways. B: corresponding representative time course 
of changes in luminal area of the same PCLS preparations in saline-control (left) and allergen-
sensitized (right) airways after MC treatment.  C: Dose-response curve obtained by plotting the 
normalized luminal area versus logarithm of MC concentration in saline-control ( , n = 3) and 
allergen-sensitized (∎, n = 2) airways. EC50 values were obtained by fitting the data to the five-
parameter, variable-slope equation using GraphPad® Prism software (La Jolla, CA). Dose-response 
curve for MC in saline-control guinea pigs gave an EC50 = 72.0 nM, while the EC50 of MC in allergen-
sensitized guinea pigs was calculated to be 28.7 nM.  
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Figure19. Kv7 Channel activator retigabine (R) attenuated histamine (H)-induced constriction 
of saline-control and allergen-sensitized airways. A: Representative images of a small airway 
from saline-control and allergen-sensitized airways in the presence of 50 nM histamine (50 nM H) 
alone, and 50 nM histamine applied with 10 µM retigabine after complete recovery from the first 
treatment (50 nM H + 10 µM R). B: corresponding representative time course of changes in luminal 
area of the same small airways. C: summarized bar graph of the percentage of 50 nM histamine 
induced constriction after histamine + retigabine treatment, data normalized to 50 nM histamine 
treatment. Luminal area was measured during the last min of treatment with 50 nM H and 50 nM H + 
10 µM R. 
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Kv7 channel activator attenuates histamine-induced bronchoconstriction in 
guinea pig airways: After determining the EC50 values of histamine and 
methacholine in saline-control and allergen-sensitized airways, we wanted to study 
if the bronchoconstriction effect on allergen-sensitized airways can be attenuated 
with Kv7 channel activators.  Histamine was selected for these studies because it 
showed a distinctly potentiated effect in allergen-sensitized airways. We treated 
PCLS preparations from saline-control and allergen-sensitized airways with a near 
EC50 concentration of histamine (50 nM) as measured in allergen-sensitized 
airways. The 50 nM histamine treatment was repeated (after complete relaxation of 
the airway) in the presence of 10 µM retigabine (Kv7.2-Kv7.5 channel activator) 
(Figure 18A & B). Importantly, retigabine was able to attenuate the histamine-
mediated bronchoconstriction by ~20 % in saline-control airways and ~ 70 % in 
allergen-sensitized airways (Figure 18C). This result is significant as it supports our 
hypothesis that Kv7 channel activators can attenuate the effect of 
bronchoconstrictor agonists in allergen-sensitized airways. These studies will be 
repeated for reproducibility using PCLS preparations from a larger number of 




Figure 20. Functional Kv7 channels are required for maintaining resting diameter of small 
airways in human lung slices. A: representative images of a small airway before treatment 
(control), in the presence of 50 nM histamine applied for 5 min (50 nM Hist), in the presence of 50 
nM histamine applied with 100 µM flupirtine for 5 min (50 nM Hist + 100 µM F), following a 10-min 
washout of histamine and flupirtine (washout), and in the presence of 10 µM XE991 applied for 10 
min. B: corresponding representative time course of changes in luminal area of the same small 
airway. Both 50 nM histamine (Hist) and 50 nM histamine with 100 μM flupirtine (Hist + F) were 
applied for 5 min followed by a 10-min washout in each case; 10 μM XE-991 was applied for 10 min. 
C: summarized bar graph of average airway luminal area measured in multiple lung slices from 2 
human subjects. Luminal area measured during the last min of treatment with 50 nM histamine 
(Hist), 50 nM histamine with 100 µM flupirtine (Hist + F), or 10 µM XE991 was normalized to control 
area measured before treatments; *significant difference from control (1-way ANOVA, P < 0.001, n = 
6–8); #significant difference between histamine alone and histamine plus flupirtine treatment 
groups (paired Student’s t-test, P < 0.05, n = 6). (Adapted from: Brueggemann LI, Kakad PP, et al. 
(2012) Am J Physiol Lung Cell Mol Physiol 302(1):L120-132). 
 
control 50 nM Hist 50 nM Hist+
100 μM F
washout 10 μM XE-991
time, min











































Kv7 channel activator attenuates histamine-induced bronchoconstriction in 
human airways: The availability of human lung tissues enabled us to evaluate the 
physiological relevance of functional Kv7 channels in human airways using PCLS 
(work carried out by Dr. L. Brueggemann). Application of 50 nM histamine induced 
a 41  10% constriction of human airways (as estimated by reduction of luminal 
area). The histamine-induced constriction was slightly but significantly attenuated 
(29  10%, P = 0.014, paired Student’s t-test) in the presence of 100 µM flupirtine, 
an activator of Kv7.2–7.5 channels (Figure 19C). Application of 10 µM of XE991, a 
potent and selective inhibitor of Kv7 channels, consistently induced near total 
constriction of small airways (46–89 µm in diameter) in human lung slices (79  6% 




DISCUSSION AND CONCLUSIONS 
 Airway hyperresponsiveness (AHR), a characteristic feature of asthma, is 
marked by increased sensitivity of airways to inhaled bronchoconstrictor agonists. 
The mechanisms underlying AHR are, however, poorly understood. Airway smooth 
muscle cells (ASMCs) are the main effector cells of airway narrowing. The Kv7 
voltage-activated K+ channels are known to play an important role in regulating 
resting membrane potential of many excitable cells, however, their expression and 
function in ASMCs has never been investigated before. The research presented in 
this thesis not only studies the expression and function of Kv7 channels in ASMCs 
but also reveals a link between modulation of Kv7 channel function and AHR in 
asthmatic airways. Our results present the first evidence of Kv7 channels expression 
in guinea pig and human ASMCs. In a parallel investigation to these studies, our 
laboratory has measured K+ currents in ASMCs with the expected 
electrophysiological and pharmacological characteristics of Kv7 currents. The Gq/11-
coupled bronchoconstrictor agonists were observed to suppress Kv7 currents, but 
the currents could be restored by drugs that are selective Kv7 channel activators. 
These results motivated us to explore the functional relevance of Kv7 channels in 
further detail using ex vivo precision-cut lung slices (PCLS). Our initial PCLS studies 
revealed that Kv7 channel activators are capable of attenuating 
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bronchoconstrictor agonist induced airway constriction, highlighting an important 
contribution of these channels in maintaining the airway diameter. These findings 
also provide the first evidence in support of our key hypothesis that Kv7 channels 
have an important role to play in the pathophysiology of AHR. A series of studies 
were then performed comparing the expression of Kv7 channel subtypes in 
asthmatic airways to normal airways using a suitable model of asthma and 
examining the modulation of Kv7 channel function in diseased airways. Some of the 
key findings from our studies and their implications for our current understanding 
of AHR are discussed below.  
Kv7 channels in ASMCs  
Our findings reported in this thesis indicate that Kv7 channels are expressed 
in ASMCs. Multiple Kv7 channel subtypes were found to be expressed in both guinea 
pig and human ASMCs, although their expression pattern differed in the two species. 
Guinea pig ASMCs expressed KCNQ2>KCNQ5>KCNQ4>KCNQ3>>KCNQ1, while 
human ASMCs expressed KCNQ1>KCNQ4>KCNQ5>KCNQ3. The expression pattern 
in human ASMCs was similar to that reported in vascular smooth muscle cells 
(VSMCs) in mouse and rat arteries (expression of KCNQ1, KCNQ4, and KCNQ5, with 
little or no detectable KCNQ2 or KCNQ3) (Brueggemann et al. 2012; Joshi et al. 
2009; Yeung et al. 2007). In human arteries, only KCNQ2 was undetectable (Ng et al. 
2011). The expression pattern for KCNQ1 and KCNQ2 mRNAs was different    
between normal guinea pig and human ASMCs. KCNQ2 was the most abundant 
KCNQ transcript in guinea pig ASMCs, but was undetectable in human ASMCs, 
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whereas KCNQ1 was most abundant in human and barely detectable in guinea pig. 
The reason for these inter-species differences in Kv7 channel expression pattern 
and their functional impact on airway function still remains to be determined. The 
results from the expression studies were confirmed using immunofluorescence 
detection of Kv7 channel proteins in normal guinea pig and human ASMCs. These 
studies also indicated the presence of multiple Kv7 channel subtypes in both human 
and guinea pig ASMCs, but with similar expression patterns between the species. 
However, this method is not quantitative and the findings are highly dependent on 
the quality of available antibodies. Therefore, caution should be exercised while 
interpreting the immunofluorescence data.  
While evaluating the findings from electrophysiological studies (as discussed 
in Chapter 1) in context with the expression studies (as presented in Chapter 4), it is 
important to take into consideration that any of the expressed Kv7 channel protein 
subtypes can potentially contribute to the K+ currents measured in guinea pig or 
human ASMCs. Therefore, robust currents were detected in guinea pig ASMCs where 
KCNQ1 expression was not detected. Selective activators of Kv7.2–7.5 subtypes, 
flupirtine and retigabine, robustly enhanced the currents in both guinea pig and 
human ASMCs. Combined together, the data indicates that there is a likelihood of 
some combination of Kv7.2–7.5 subtypes forming functional channels in both guinea 
pig and human ASMCs that contribute to the regulation of airway diameter. 
When we extended the expression studies to allergen-sensitized airways 
obtained from a guinea pig model of AHR, our preliminary results (n=4) showed a 
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trend indicating a decrease in the expression of all KCNQ isoforms in allergen-
sensitized guinea pig airways compared to the saline-controls. We plan to repeat 
these experiments to increase the sample size. However, conclusions from these 
data will be drawn with caution as reduced expression of genes does not necessarily 
mean reduced presence of functional protein products, hence confirming the 
decrease in translational gene product would further strengthen our conclusions 
from the expression studies. If the expression of KCNQ genes is consistently found to 
be low, then this observation will have important implications on our understanding 
of the etiology of AHR. It will suggest to us that AHR in asthma is likely to be caused 
by bronchoconstrictor agonist-mediated suppression of genes encoding Kv7 
channel. This will initiate efforts on our part to investigate the effectors downstream 
of Gq/11 coupled receptors that are responsible for reduction in KCNQ mRNA levels 
in allergen-sensitized airways. The mRNA levels in cells can be regulated at the 
transcriptional and post-transcriptional stages (Latchman 2005). A number of 
mechanisms can potentially be involved in regulating mRNA levels at these stages. 
For example, the transcriptional regulation can result from alteration of various 
transcriptional factors, while the post-transcriptional regulation can be effected by 
modulation of capping, splicing or poly(A) tail addition processes. Therefore, it will 
be interesting to investigate the exact mechanism leading to decrease in KCNQ 
mRNA levels in allergen-sensitized guinea pig airways. Additionally, if the functional 
Kv7 channel protein level is found to be unaffected in allergen-sensitized guinea pig 
ASMCs, we will continue to perform experiments to investigate the mechanism of 
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the suppressive effect of bronchoconstrictor agonists on Kv7 channel activity as 
seen in the electrophysiological and PCLS studies (discussed in next section).  
Kv7 channel activity in ASMCs and its significance in AHR 
AHR, in simple terms, can be defined as airways that constrict “too easily” 
and “too much” in response to particular stimuli.  A number of pharmacological (eg. 
bronchoconstrictor agonists), chemical (eg. allergens) and physical (eg. exercise) 
stimuli can lead to such an exaggerated response. The diagnosis of asthma is 
generally made when bronchoconstrictor agonists that act directly on ASMCs induce 
constriction of airways at lower than normal concentrations, or when airways 
constrict with a lower threshold of indirect bronchial provocation (e.g., exercise or 
inhalation of cold air). In agreement with these well documented facts, our 
bronchoconstrictor agonist dose-response studies using PCLS preparations showed 
increased sensitivity to histamine and methacholine in allergen-sensitized guinea 
pigs compared to the saline control. There was an approximate 4.5-fold decrease in 
the EC50 value for histamine and ~2.5-fold decrease in the EC50 value for 
methacholine in allergen-sensitized guinea pig airways compared to saline control. 
Importantly, in addition to the increased airway sensitivity, there was a notable 
increase in the Emax values in allergen-sensitized airways indicating a concomitant 
increase in the magnitude of constriction. Thus the allergen-sensitized guinea pig 
airways constricted “too easily” and “too much” in response to bronchoconstrictor 
agonist, suggesting airway hyper-sensitization. The hyper-sensitization of airways 
was also confirmed by application of ovalbumin (chemical stimulus) to the allergen-
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sensitized PCLS preparation. Passive challenge with 1 µg/ml of ovalbumin 
completely constricted airways that were actively sensitized.  
The underlying mechanism for increased sensitivity of airways to multiple 
direct and indirect stimuli in asthma patients is one of the key questions that remain 
unanswered. In line with our working hypothesis, a possible mechanism for 
sensitization of ASMCs to multiple bronchoconstrictor stimuli could be a reduction 
in K+ channel activity associated with an increase in electrical resistance of ASMC 
plasma membrane. According to Ohm’s law, voltage is proportional to the product of 
current and resistance. Therefore, an increase in resistance would enable a small 
current to produce a larger change in voltage. In other words, a reduction in 
outward K+ currents would increase membrane resistance and thereby serve to 
sensitize ASMCs to depolarizing stimuli (depolarizing stimuli include small 
increases in inward current, e.g., due to activation of Cl- or cation channels in 
response to bronchial provocation). Thus bronchial provocation would tend to 
induce greater membrane depolarization and activation of voltage-sensitive calcium 
channels (VSCC) when K+ channel activity is reduced. Such a mechanism is 
consistent with the observation that the sensitivity of porcine trachealis muscle to 
histamine-induced contraction was enhanced in the presence of a nonspecific K+ 
channel blocker (tetraethylammonium, 10 mM), and that this effect was abolished 
by the calcium channel blocker verapamil (Mitchell et al. 1987). If Kv7 channel 
activity in ASMCs were reduced in asthma, bronchial provocation by 
pharmacological or mechanical stimulation would more effectively depolarize the 
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cells to activate L-type VSCC and enhance airway constriction. Our preliminary 
results from Kv7 channel expression studies in allergen-sensitized airways indeed 
suggest a decrease in Kv7 channel expression level that may lead to reduced Kv7 
channel activity. Conversely, increasing Kv7 channel activity would reduce ASMC 
electrical excitability and decrease the sensitivity to bronchial provocation. In 
agreement with this hypothesis, our PCLS studies in normal guinea pigs indicate a 
dose-dependent constriction of airways with histamine and attenuation of this 
response in the presence of Kv7 channel activator, retigabine. Similarly, despite 
their reduced expression in allergen-sensitized airways, we believe that an increase 
in the activity of the remaining Kv7 channels is likely to decrease the sensitivity of 
allergen-sensitized airways to bronchial provocation. In our investigation of this 
effect we observed a dose-dependent constriction of allergen-sensitized airways 
with histamine and significant attenuation of this response in the presence of Kv7 
channel activator, retigabine.  Therefore, these results provide us an insight in to 
how Kv7 channel expression and function in airways play a role in regulation of 
airway diameter. Importantly, the attenuation of bronchoconstrictor agoinst-
mediated airway constriction by Kv7 channel activators in allergen-sensitized 
airways indicates promising application of Kv7 channel activators in treatment of 
airway hyperresponsiveness.  
Pharmacological targeting of Kv7 channels in ASMCs 
Bronchoconstrictor agonists depolarize ASMC membrane potentials positive 
to the L-type VSCC activation threshold which is likely to activate L-type VSCC 
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leading to influx of Ca+2 and bronchoconstriction (Hirota et al. 2007). Therefore, an 
effective way of antagonizing agonist induced bronchoconstrictor effect is to block 
L-type VSCC. As discussed in chapter 1, a number of clinical trials were conducted in 
the early 1980’s to evaluate the efficacy of L-type Ca2+ channel blockers (CCBs) in 
the treatment of asthma. The results were inconsistent, although almost all the 
clinical trials revealed at least a subset of patients who benefited from treatment 
with either verapamil or nifedipine (Fish et al. 1984). Taken as a whole, the clinical 
trials revealed that asthma patients benefit from treatment with CCBs, but the 
efficacy of these agents is limited because of adverse side effects associated with 
systemic administration and limitations of formulation that prevent delivery of 
effective doses of verapamil or nifedipine by inhalation (Fish et al. 1984). Our 
ongoing studies have indicated that the bronchoconstrictor effect of histamine at 
lower concentration (≤ 1 μM) is effectively attenuated by CCBs like verapamil. 
However, verapamil is not effective in attenuating the effect of histamine used in 
higher concentrations (10 μM), thus indicating that at high agonist concentration, 
the bronchoconstrictor effect of histamine is independent of L-type VSCC. This is in 
agreement with the previously published study from our laboratory, showing 
concentration dependent signaling of Gq/11 receptor agonist vasopressin (AVP) in 
vascular smooth muscle cells (VSMCs) (Henderson et al. 2007). The local 
concentration of histamine in normal and allergen-sensitized airways is not known 
but given the fact that CCBs show significant protection against bronchoconstriction 
induced by exogenously administered histamine in human subjects (Cuss et al. 
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1985). It remains to be determined whether the local histamine concentration in 
asthmatic airways is in the range where CCBs are effective.  
The Kv7 channel activators, by means of their membrane repolarizing 
property, can ultimately have the same effect of reducing Ca2+ influx in ASMCs as 
with CCBs therapy.  Although our studies suggest reduced expression of Kv7 
channels in allergen-sensitized airways, it was also observed that Kv7 channel 
activator, retigabine, can attenuate the bronchoconstrictor agonist-mediated 
constriction, possibly by enhancing the activity of the remaining Kv7 channels. In 
general, Kv7 channel activators have well-established clinical safety profiles when 
administered systemically, and it may also be possible to develop inhalational 
formulations of these drugs, which would reduce off-target effects. Furthermore, if 
the Kv7 channel subunit stoichiometry in ASMCs differs from that of channels found 
in other tissues, it may be possible to develop drugs that have selectivity for ASMC 
Kv7 channels further improving their safety profile.  
If we reproducibly measure decreased level of KCNQ mRNA in allergen-
sensitized guinea pig airways, we will focus our efforts in identifying transcriptional 
or post-transcriptional events that lead to reduced KCNQ mRNA levels. Depending 
on the mechanism responsible for reduced expression, gene therapy would be a 
viable therapeutic approach. Gene therapy has shown tremendous potential in the 
treatment of disease like cystic fibrosis by replacement of mutated Cystic Fibrosis 
Transmembrane Regulator (CFTR) gene (Corbyn 2012). Gene thearpy is a promising 
approach as it targets the cause of a disease rather than just controlling the 
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symptoms.  However, the success of this approach would depend on the mechanism 
that is responsible for reduced mRNA levels in allergen-sensitized airways.  
Summary 
In summary, our results reveal a novel and fundamental mechanism for regulating 
airway diameter. Our studies demonstrate that the activity of Kv7 potassium 
channels in ASMCs under resting conditions is essential to maintain the relaxed 
state of the airways. Preliminary findings suggest that bronchial provocation of 
airways with a known allergen reduces the expression of Kv7 channels. Ultimately, 
this may lead to potentiation of the bronchoconstrictor effects mediated by 
bronchoconstrictor agonists, and thereby account for airway hypersensitization. 
Our results also provide evidence that despite the reduced expression of Kv7 
channel in diseased airways, Kv7 channel activators are still effective in attenuating 
the bronchoconstrictor effect of a bronchoconstrictor agoinst, indicating that these 
drugs may be useful in the treatment of airway hyperconstriction in asthma or other 
airway diseases. After confirming that there is a proportionate decrease in the 
functional Kv7 channel protein as a result of reduced KCNQ genes expression, it will 
be interesting to investigate the underlying mechanisms of the decreased Kv7 
channel expression upon bronchial provocation. 
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